Literature DB >> 19656890

Stimulus duration and response time independently influence the kinetics of lytic cycle reactivation of Epstein-Barr virus.

Jill Countryman1, Lyndle Gradoville, Sumita Bhaduri-McIntosh, Jianjiang Ye, Lee Heston, Sarah Himmelfarb, Duane Shedd, George Miller.   

Abstract

Epstein-Barr virus (EBV) can be reactivated from latency into the lytic cycle by many stimuli believed to operate by different mechanisms. Cell lines containing EBV differ in their responses to inducing stimuli, yet all stimuli require de novo protein synthesis (44). A crucial step preliminary to identifying these proteins and determining when they are required is to measure the duration of stimulus and response time needed for activation of expression of EBV BRLF1 and BZLF1, the earliest viral indicators of reactivation. Here we show, with four EBV-containing cell lines that respond to different inducing agents, that stimuli that are effective at reactivating EBV can be divided into two main groups. The histone deacetylase inhibitors sodium butyrate and trichostatin A require a relatively long period of exposure, from 2 to 4 h or longer. Phorbol esters, anti-immunoglobulin G (anti-IgG), and, surprisingly, 5-aza-2'-deoxycytidine require short exposures of 15 min or less. The cell/virus background influences the response time. Expression of the EBV BZLF1 and BRLF1 genes can be detected before 2 h in Akata cells treated with anti-IgG, but both long- and short-duration stimuli required 4 or more hr to activate BZLF1 and BRLF1 expression in HH514-16, Raji, or B95-8 cells. Thus, stimulus duration and response time are independent variables. Neither stimulus duration nor response time can be predicted by the number of cells activated into the lytic cycle. These experiments shed new light on the earliest events leading to lytic cycle reactivation of EBV.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19656890      PMCID: PMC2753116          DOI: 10.1128/JVI.01172-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation.

Authors:  L K Chang; S T Liu
Journal:  Nucleic Acids Res       Date:  2000-10-15       Impact factor: 16.971

2.  12-O-tetradecanoylphorbol-13-acetate induces Epstein-Barr virus reactivation via NF-kappaB and AP-1 as regulated by protein kinase C and mitogen-activated protein kinase.

Authors:  X Gao; K Ikuta; M Tajima; T Sairenji
Journal:  Virology       Date:  2001-07-20       Impact factor: 3.616

3.  A histone deacetylase inhibitor, azelaic bishydroxamic acid, shows cytotoxicity on Epstein-Barr virus transformed B-cell lines: a potential therapy for posttransplant lymphoproliferative disease.

Authors:  Tom B Sculley; Marion Buck; Brian Gabrielli; Peter G Parsons; Kenia G Krauer
Journal:  Transplantation       Date:  2002-01-27       Impact factor: 4.939

4.  Histone acetylation and reactivation of Epstein-Barr virus from latency.

Authors:  P J Jenkins; U K Binné; P J Farrell
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.

Authors:  E M Westphal; W Blackstock; W Feng; B Israel; S C Kenney
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

6.  Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle.

Authors:  Lyndle Gradoville; David Kwa; Ayman El-Guindy; George Miller
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 7.  Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.

Authors:  S J Mentzer; S P Perrine; D V Faller
Journal:  Transpl Infect Dis       Date:  2001-09       Impact factor: 2.228

8.  MEF2-mediated recruitment of class II HDAC at the EBV immediate early gene BZLF1 links latency and chromatin remodeling.

Authors:  H Gruffat; E Manet; A Sergeant
Journal:  EMBO Rep       Date:  2002-01-29       Impact factor: 8.807

9.  Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB.

Authors:  Jeena Joseph; Giridhar Mudduluru; Sini Antony; Surabhi Vashistha; Parthasarathi Ajitkumar; Kumaravel Somasundaram
Journal:  Oncogene       Date:  2004-08-19       Impact factor: 9.867

10.  Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.

Authors:  Constantine S Mitsiades; Nicholas S Mitsiades; Ciaran J McMullan; Vassiliki Poulaki; Reshma Shringarpure; Teru Hideshima; Masaharu Akiyama; Dharminder Chauhan; Nikhil Munshi; Xuesong Gu; Charles Bailey; Marie Joseph; Towia A Libermann; Victoria M Richon; Paul A Marks; Kenneth C Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-26       Impact factor: 11.205

View more
  15 in total

1.  Epstein-Barr virus LF2 protein regulates viral replication by altering Rta subcellular localization.

Authors:  Andreas M F Heilmann; Michael A Calderwood; Eric Johannsen
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

2.  Viral response to chemotherapy in endemic burkitt lymphoma.

Authors:  Weihua Tang; Paula Harmon; Margaret L Gulley; Charles Mwansambo; Peter N Kazembe; Francis Martinson; Clifford Wokocha; Shannon C Kenney; Irving Hoffman; Carlie Sigel; Susan Maygarden; Mariah Hoffman; Carol Shores
Journal:  Clin Cancer Res       Date:  2010-03-16       Impact factor: 12.531

3.  Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr Virus.

Authors:  Nadezhda Tikhmyanova; David C Schultz; Theresa Lee; Joseph M Salvino; Paul M Lieberman
Journal:  ACS Chem Biol       Date:  2014-02-19       Impact factor: 5.100

4.  Role of RNF4 in the ubiquitination of Rta of Epstein-Barr virus.

Authors:  Ya-Chun Yang; Yushi Yoshikai; Shih-Wei Hsu; Hisato Saitoh; Li-Kwan Chang
Journal:  J Biol Chem       Date:  2013-03-15       Impact factor: 5.157

5.  Cellular immediate-early gene expression occurs kinetically upstream of Epstein-Barr virus bzlf1 and brlf1 following cross-linking of the B cell antigen receptor in the Akata Burkitt lymphoma cell line.

Authors:  Jianjiang Ye; Lyndle Gradoville; George Miller
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

6.  Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle.

Authors:  Derek Daigle; Lyn Gradoville; David Tuck; Vince Schulz; Ruth Wang'ondu; Jianjiang Ye; Kelly Gorres; George Miller
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

7.  Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells.

Authors:  Takayuki Murata; Yutaka Kondo; Atsuko Sugimoto; Daisuke Kawashima; Shinichi Saito; Hiroki Isomura; Teru Kanda; Tatsuya Tsurumi
Journal:  J Virol       Date:  2012-02-22       Impact factor: 5.103

8.  Development of a novel inducer for EBV lytic therapy.

Authors:  Nadezhda Tikhmyanova; Nicholas Paparoidamis; James Romero-Masters; Xin Feng; Farheen Sultana Mohammed; Poli Adi Narayana Reddy; Shannon C Kenney; Paul M Lieberman; Joseph M Salvino
Journal:  Bioorg Med Chem Lett       Date:  2019-06-22       Impact factor: 2.823

9.  Activation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids.

Authors:  Kelly L Gorres; Derek Daigle; Sudharshan Mohanram; George Miller
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

10.  Histone Deacetylase Inhibitors Romidepsin and Vorinostat Promote Hepatitis B Virus Replication by Inducing Cell Cycle Arrest.

Authors:  Yang Yang; Yu Yan; Zhen Chen; Jie Hu; Kai Wang; Ni Tang; Xiaosong Li; Zhi Zhou
Journal:  J Clin Transl Hepatol       Date:  2021-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.